Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17249586 | 1.00 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL20808829 | 0.89 | ALDH1A1 (0.42) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL20005894 | 0.78 | SMN1; SMN2 (0.35) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL20808598 | 0.76 | SMN1; SMN2 (0.33) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL18677751 | 0.76 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2GAANFKB1NFKB2 | |
| SCHEMBL20005893 | 0.74 | NFKB1 (0.34) | ALDH1A1SMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL10029239 | 0.74 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL405246 | 0.74 | ALDH1A1 (0.71) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 | |
| SCHEMBL20145995 | 0.71 | NFKB1 (0.32) | NFKB1NFKB2RELA | |
| SCHEMBL10029261 | 0.71 | ALDH1A1 (0.76) | ALDH1A1SMN1; SMN2GAAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862683-B2 | Methods of preparing Tecovirimat | SIGA TECHNOLOGIES, INC. (US) | 2018-01-09 | — | — | US | disclosed |
| US-20170088517-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546137-B2 | Methods of preparing Tecovirimat | SIGA TECHNOLOGIES INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150322010-A1 | METHODS OF PREPARING TECOVIRIMAT | SIGA TECHNOLOGIES INC. (US) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322010-A1 | METHODS OF PREPARING TECOVIRIMAT | TYMP, NUDT1, HPRT1 | ALDH1A1 2593/4885SMN1; SMN2 672/4885GAA 129/4885 |
| US-20170088517-A1 | METHODS OF PREPARING TECOVIRIMAT | TYMP, NUDT1, HPRT1 | ALDH1A1 2593/4885SMN1; SMN2 672/4885GAA 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.